EDWARDS JAMES P
No ORCID on file
· 63 papers in corpus
· active 2000-2004
Frequent coauthors
- TEGLEY Christopher M. 63
- JONES Todd K. 63
- ZHI Lin 60
- WROBEL Jay E. 60
- GRUBB Gary S. 60
- FENSOME Andrew 54
- ZHANG Puwen 48
- TEREFENKO Eugene A. 33
- BENDER Reinhold H. W. 15
- ULLRICH John W. 15
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
2004
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
2004
A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …
2003
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single sub…
2003
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single sub…
2003
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single sub…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having the general structure: wherein: R1, and R2 are chosen indep…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having the general structure: wherein: R1, and R2 are chosen indep…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having the general structure: wherein: R1, and R2 are chosen indep…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein R1 and R2 may be single substitu…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein R1 and R2 may be single substitu…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein R1 and R2 may be single substitu…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (1) wherein: A is O, S, or NR4; B is a bond …
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (1) wherein: A is O, S, or NR4; B is a bond …
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (1) wherein: A is O, S, or NR4; B is a bond …
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having general structure (I) wherein: R1, and R2 are chosen independen…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having general structure (I) wherein: R1, and R2 are chosen independen…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having general structure (I) wherein: R1, and R2 are chosen independen…
2002
This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (I): wherein R1 and R2 may be single substit…